SM
XLRN

Sabby Management’s Acceleron Pharma XLRN Stock Holding History

Sabby Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-55
Closed -$215K – 196
2018
Q1 		$215K Buy
+55
New +$2.34K 0.03% 119
2017
Q2 		– Sell
-92
Closed -$244K – 277
2017
Q1 		$244K Buy
+92
New +$2.42K 0.01% 211

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sabby Management's XLRN Position: Q2 2018 in Review

Sabby Management sold out of Acceleron Pharma (XLRN) in Q2 2018, closing a stake of 8,646 shares — an estimated $338K sold.

Sabby Management first reported a position in XLRN in Q1 2016 and held it in 2 quarters. The position peaked at $1.32M in Q1 2016. 170 funds tracked by Wall St. Rank hold XLRN as of Q2 2018.

  • Sabby Management reported no remaining Acceleron Pharma position as of Q2 2018 after selling out during the quarter.
  • Sabby Management sold 8,646 Acceleron Pharma shares in Q2 2018, an estimated $338K.
  • Sabby Management first reported a position in Acceleron Pharma in Q1 2016 and held it in 2 quarters.
  • Sabby Management's Acceleron Pharma position peaked at $1.32M in Q1 2016.
  • 170 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.